ArticlePediatric research2026
Risk factors for cutaneous complications of advanced therapies in paediatric inflammatory bowel disease patients.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObservational data suggest comparable efficacy of different advanced therapies in paediatric inflammatory bowel disease (pIBD). Cutaneous adverse effects (cAEs) of tumour necrosis factor antagonists (anti-TNF) may lead to treatment discontinuation. Identifying risk factors for these adverse effects could improve treatment sustainability.
methodsWe conducted a prospective, multicentre observational study using Czech registry data. pIBD patients treated with anti-TNF, vedolizumab or ustekinumab were enroled. The primary outcome assessed was time to the onset of cAEs. The secondary outcome was time to the onset of severe cAEs. Multivariate Cox proportional hazards models with mixed effects were used with predefined clinically important confounders.
resultsWe analysed 546 treatment courses from 423 patients across four centres. cAEs were reported in 19.8% of therapy courses and were associated with female sex [hazard ratio (HR) 1.82, 95% confidence interval (CI): 1.18-2.81], a family history of atopic diseases (HR: 1.82, 95% CI: 1.13-2.91) and anti-TNF therapy (HR: 6.84, 95% CI 1.98-23.63).
conclusionWe demonstrated a strong association between cAEs and anti-TNF treatment, female sex and a family history of atopic diseases. Non-anti-TNF advanced therapy may be considered early for patients at risk for cAEs. IMPACT: Cutaneous adverse effects occur in up to 20% of advanced therapy courses in paediatric inflammatory bowel disease, with approximately half being severe. Female sex and a family history of atopic disease are associated with an increased risk of cutaneous adverse effects. Among patients requiring a change in advanced therapy due to cutaneous adverse effects, switching to ustekinumab is associated with higher odds of resolution compared with switching to another anti-TNF agent. Early use of non-anti-TNF agents may be considered in paediatric patients at higher risk of cutaneous adverse effects.
Identifiers
42323484What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.